Omalizumab (anti-IgE) is effective in the allergic asthma phenotype, while mepolizumab and reslizumab (anti-IL5) and benralizumab (anti-IL5Rα) target eosinophilic inflammation, which is strongly associated with frequent exacerbations. Here, IGHE is linked to allergic asthma.